<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461900</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC18.0054 (GOAL)</org_study_id>
    <nct_id>NCT03461900</nct_id>
  </id_info>
  <brief_title>Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock</brief_title>
  <acronym>GOAL</acronym>
  <official_title>Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock: A Multicenter, Stepped Wedge Cluster Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many observational studies have highlighted an independent association between fluid overload
      and clinical outcomes during septic shock. To optimize fluid balance, clinician has several
      options to consider carefully fluid administration and avoid fluid overload. More than a
      general restrictive approach, a pragmatic, individual tailored approach should be considered
      to optimize patients' hemodynamics during acute circulatory failure. Many advances in
      hemodynamic monitoring were described. Mini-fluid challenge appears to be a sensible method
      to use for bedside assessment to optimize fluid infusion. The next step for hemodynamic
      management in the ICU should be to test a hemodynamic goal-directed approach to better
      control fluid management and eventually improve patient's outcome. The main objective of the
      GOAL study is to evaluate a pragmatic optimization fluid management protocol tailored to each
      patient's hemodynamic status based on mini-fluid challenges. This intervention will be
      compared to usual management based on the latest guidelines. This intervention aims to
      decrease organ dysfunction during septic shock. This is the first large clinical trial
      designed to test this hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GOAL study is a stepped wedge cluster-randomized trial. Centers will switch randomly from the
      control to the intervention at regular intervals:

        -  Control periods: Patients receive a usual optimization fluid management according to
           surviving sepsis campaign guidelines.

        -  Interventional periods: Patients receive a pragmatic, protocolized and individual
           optimization fluid management according to validated components of a hemodynamic
           challenges called Mini-Fluid Challenge (MFC).

      Except fluid therapy in interventional group, management of sepsis will be at the discretion
      of the attending physician. The use of international guidelines for all therapeutic
      interventions is recommended in all patients whenever their group.

      All patients will be followed from enrollment to death or hospital discharge. If alive but
      not in the hospital after 28 days since septic shock, clinical outcomes will be evaluated by
      a visit with an intensivist or, if a physical examination is not possible, by a telephone
      interview performed by an intensivist. To ensure the same data collection in all centers, six
      visits were planned: D1 (inclusion), D3, D10, D28, D90 D180.

      Classical blinded methods cannot be used in case of evaluation of an optimization protocol.
      Investigators are unblinded to which arm patient is randomized. To ensure the same evaluation
      for all patients and in all centers, all events recorded will be evaluated by an independent
      clinical event committee.

      All primary endpoints will be analyzed according to a hierarchized analysis to ensure
      comparison of multiple issues without considering type I error inflation. Secondary outcomes
      will be analyzed as exploratory analysis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>stepped wedge cluster randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta SOFA score (Day0 - Day5)</measure>
    <time_frame>Day 5</time_frame>
    <description>Delta SOFA score is the difference between SOFA (Sepsis-related Organ Failure Assessment) measured at day 0 and at Day 5. SOFA score was developed to quantify organ dysfunction in patients with sepsis and to determine treatment effectiveness. SOFA score is a scale range from 0 to 24, with higher scores indicating worse organ dysfunction. Five organs dysfunctions are analyzed:
Respiratory: PaO2/FiO2 ratio
Cardio-vascular: severity of hypotension and need of vasopressors (µ/kg/min)
Renal: creatinine (mg/dl)
Hemostasis: Platelet count (G/l)
Liver: Bilirubin (mg/dl)
Neurologic: Glasgow coma scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilator free days at day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal failure free days at day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Catecholamine free days at day 10</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>SF-36 (Short-Form 36)</measure>
    <time_frame>6 months</time_frame>
    <description>The SF-36 is an indicator of health status and quality of life. The SF-36 has eight dimensions; the scores are weighted sums of the questions in each section. This scores range from 0 - 100. Lower scores indicate more disability and higher scores less disability.
The eight dimensions of this score are:
Vitality
Physical functioning
Bodily pain
General health perceptions
Physical role functioning
Emotional role functioning
Social role functioning
Mental health</description>
  </other_outcome>
  <other_outcome>
    <measure>RBANS (Repeatable Battery for the Assessment of Neuropsychological Status)</measure>
    <time_frame>6 months</time_frame>
    <description>The RBANS is a comprehensive and validated neuropsychometric battery for the evaluation of global cognition. RBANS comprises of 12 sub-tests that are combined to form 5 index scores and a total score. This score is used to evaluate long term cognitive impairment. The population age-adjusted mean (±SD) for the RBANS global cognition score and for the individual domains is 100±15 (on a scale ranging from 40 to 160, with lower scores indicating worse performance). The indexes (and sub-tests) are:
Immediate Memory (List Learning, Story Memory)
Visuospatial/Constructional (Figure Copy, Line Orientation);
Language (Picture Naming, Semantic Fluency)
Attention (Digit Span, Coding)
Delayed Memory (List Recall, List Recognition, Story Recall, Figure Recall).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">711</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Minifluid challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 ml of 4% Albumin will be deliver to assess fluid responsiveness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be treated as defined by most recent surviving sepsis campaign guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Minifluid challenge</intervention_name>
    <description>Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.</description>
    <arm_group_label>Minifluid challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual practice</intervention_name>
    <description>Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient (Age &gt; 18 years) admitted in ICU for less than 3 days.

          -  Abdominal (excepted urinary tract infection) or pulmonary related septic shock,
             defined by SEPSIS III criteria diagnosed within less than 12 hours.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Patient with life expectancy inferior to 24 hours

          -  Cardiac arrest

          -  Albumin allergy

          -  Pregnancy

          -  Traumatic brain injury

          -  Patients admitted for more than 3 days in ICU

          -  Limitation of invasive therapeutics, palliative care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Huet, MD, PhD</last_name>
    <phone>+33298347449</phone>
    <email>olivier.huet@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angers university hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigismond Lasocki, MD, PhD</last_name>
      <phone>+33241355940</phone>
      <email>sigismond@lasocki.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Besançon university hospital</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Capellier, MD, PhD</last_name>
      <phone>+33381668166</phone>
      <email>gilles.capellier@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brest university hospital</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brest university hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenael Prat, MD</last_name>
      <phone>+33298347181</phone>
      <email>gwenael.prat@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont Tonnerre military hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ba-Vinh Nguyen, MD, PhD</last_name>
      <phone>+33298347288</phone>
      <email>ba-vinh.nguyen@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand university hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Futier, MD, PhD</last_name>
      <phone>+33473750476</phone>
      <email>efutier@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Mans hospital</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mickael Landais, MD</last_name>
      <phone>+33243432458</phone>
      <email>mlandais@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lorient hospital</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Quiniot, MD</last_name>
      <phone>+33297069090</phone>
      <email>p.quinio@ch-bretagne-sud.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille university horpital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Leon, MD, PhD</last_name>
      <phone>+33491968650</phone>
      <email>marc.leone@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille university hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Papazian, MD, PhD</last_name>
      <phone>+33491968650</phone>
      <email>laurent.papazian@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morlaix hospital</name>
      <address>
        <city>Morlaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Yves Egreteau, MD</last_name>
      <phone>+33298626095</phone>
      <email>PEgreteau@ch-morlaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes university hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karim Asehnoune, MD, PhD</last_name>
      <phone>+33240083005</phone>
      <email>karim.asehnoune@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Pompidou university hospital (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Cholley, MD, PhD</last_name>
      <phone>+33156093351</phone>
      <email>bernard.cholley@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicêtre university hospital (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Duranteau, MD, PhD</last_name>
      <phone>+33145213936</phone>
      <email>jacques.duranteau@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poitiers university hospital</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Dahyot-Fitzelier, MD, PhD</last_name>
      <phone>+33549444444</phone>
      <email>claire.dahyot@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen university hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit Veber, MD, PhD</last_name>
      <phone>+33232888292</phone>
      <email>benoit.veber@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulon hospital</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Durand-Gasselin, MD</last_name>
      <phone>+33494145000</phone>
      <email>Jacques.durand-gasselin@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours university hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Rémerand, MD, PhD</last_name>
      <phone>+33247474747</phone>
      <email>f.remerand@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.</citation>
    <PMID>24638143</PMID>
  </reference>
  <reference>
    <citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.</citation>
    <PMID>11794169</PMID>
  </reference>
  <reference>
    <citation>Malbrain ML, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, Van Regenmortel N. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 2014 Nov-Dec;46(5):361-80. doi: 10.5603/AIT.2014.0060. Review.</citation>
    <PMID>25432556</PMID>
  </reference>
  <reference>
    <citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</citation>
    <PMID>28101605</PMID>
  </reference>
  <reference>
    <citation>Sakr Y, Rubatto Birri PN, Kotfis K, Nanchal R, Shah B, Kluge S, Schroeder ME, Marshall JC, Vincent JL; Intensive Care Over Nations Investigators. Higher Fluid Balance Increases the Risk of Death From Sepsis: Results From a Large International Audit. Crit Care Med. 2017 Mar;45(3):386-394. doi: 10.1097/CCM.0000000000002189.</citation>
    <PMID>27922878</PMID>
  </reference>
  <reference>
    <citation>Marik PE, Linde-Zwirble WT, Bittner EA, Sahatjian J, Hansell D. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database. Intensive Care Med. 2017 May;43(5):625-632. doi: 10.1007/s00134-016-4675-y. Epub 2017 Jan 27.</citation>
    <PMID>28130687</PMID>
  </reference>
  <reference>
    <citation>Cecconi M, Hofer C, Teboul JL, Pettila V, Wilkman E, Molnar Z, Della Rocca G, Aldecoa C, Artigas A, Jog S, Sander M, Spies C, Lefrant JY, De Backer D; FENICE Investigators; ESICM Trial Group. Fluid challenges in intensive care: the FENICE study: A global inception cohort study. Intensive Care Med. 2015 Sep;41(9):1529-37. doi: 10.1007/s00134-015-3850-x. Epub 2015 Jul 11. Erratum in: Intensive Care Med. 2015 Sep;41(9):1737-8. multiple investigator names added.</citation>
    <PMID>26162676</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Fluid optimisation</keyword>
  <keyword>Minifluid challenge</keyword>
  <keyword>Fluid overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

